John Cullity
Vermogen: 4 M $ op 30-06-2026
Vermogen: 4 M $ op 30-06-2026
John Cullity is currently the Chairman at HaemaLogiX Pty Ltd. He is also a Director at Theraly Fibrosis, Inc. and a Managing Director at Biosynergy Partners LLC.
Additionally, he is a Member at The Royal College of Physicians.
In his former positions, Dr. Cullity served as a Director of Health Economics at Merk Sharp & Dohme (Holdings) Pty Ltd. and Sanofi-Aventis Healthcare Pty Ltd. He was also a Non-Executive Director at Race Oncology Ltd. from 2018 to 2023 and a Director at Ceramedix Holdings LLC from 2015 to 2020.
Furthermore, he held the position of Senior Member-Business Development at Sanofi-Synthelabo, Inc. and worked as a Principal at Torreya Partners LLC from 2010 to 2017.
Dr. Cullity obtained a graduate degree from the London School of Economics & Political Science.
He also holds an undergraduate degree from The University of Western Australia and an MBA from The Wharton School of the University of Pennsylvania.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
RACURA ONCOLOGY LTD 1,37% | 08-08-2025 | 2.694.642 ( 1,37% ) | 4 M $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
Biosynergy Partners LLC | Corporate Officer/Principal | 01-09-2013 |
Theraly Fibrosis, Inc.
Theraly Fibrosis, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Directeur/Bestuurslid | 01-09-2016 |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology Develops immunotherapies for blood cancers and B cell disorders | Voorzitter | - |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| RACURA ONCOLOGY LTD | Voorzitter | 20-04-2023 |
Ceramedix Holdings LLC
Ceramedix Holdings LLC Pharmaceuticals: MajorHealth Technology Operates as a biotherapeutics company that develops antibody-based drugs | Directeur/Bestuurslid | 01-03-2020 |
Torreya Partners LLC
Torreya Partners LLC Investment ManagersFinance Provides financial advisory services | Corporate Officer/Principal | 01-01-2017 |
Sanofi-Aventis Healthcare Pty Ltd. | Corporate Officer/Principal | - |
Merk Sharp & Dohme (Holdings) Pty Ltd.
Merk Sharp & Dohme (Holdings) Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceuticals products | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 13 |
|---|---|
London School of Economics & Political Science
London School of Economics & Political Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Western Australia
The University of Western Australia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Royal College of Physicians
The Royal College of Physicians Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Synthelabo, Inc. | Health Technology |
Merk Sharp & Dohme (Holdings) Pty Ltd.
Merk Sharp & Dohme (Holdings) Pty Ltd. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceuticals products | Health Technology |
Torreya Partners LLC
Torreya Partners LLC Investment ManagersFinance Provides financial advisory services | Finance |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis Healthcare Pty Ltd. | |
Race Oncology Ltd.
Race Oncology Ltd. Pharmaceuticals: MajorHealth Technology Manufactures drugs for cancer | Health Technology |
Theraly Fibrosis, Inc.
Theraly Fibrosis, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology Develops immunotherapies for blood cancers and B cell disorders | Health Technology |
Biosynergy Partners LLC | |
Ceramedix Holdings LLC
Ceramedix Holdings LLC Pharmaceuticals: MajorHealth Technology Operates as a biotherapeutics company that develops antibody-based drugs | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau